Aventis’s ‘poison pill’ raises market concerns
Sanofi’s e50bn (£33.64bn) takeover of Aventis has provoked debate among the companies’ legal advisers about the importance of France’s first ‘poison pill’. The so-called ‘poison pill’ centres on the ‘Plavix warrants’, a product that would reimburse Aventis’s shareholders in the event of Sanofi being unsuccessful in pending US patent litigation over its cancer drug Plavix. […]